ChengDa Pharmaceuticals Co. Ltd. (301201) - Net Assets
Based on the latest financial reports, ChengDa Pharmaceuticals Co. Ltd. (301201) has net assets worth CN¥2.16 Billion CNY (≈ $315.88 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.41 Billion ≈ $352.46 Million USD) and total liabilities (CN¥249.97 Million ≈ $36.58 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ChengDa Pharmaceuticals Co. Ltd. asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.16 Billion |
| % of Total Assets | 89.62% |
| Annual Growth Rate | 43.1% |
| 5-Year Change | 367.56% |
| 10-Year Change | N/A |
| Growth Volatility | 123.73 |
ChengDa Pharmaceuticals Co. Ltd. - Net Assets Trend (2019–2024)
This chart illustrates how ChengDa Pharmaceuticals Co. Ltd.'s net assets have evolved over time, based on quarterly financial data. Also explore 301201 current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for ChengDa Pharmaceuticals Co. Ltd. (2019–2024)
The table below shows the annual net assets of ChengDa Pharmaceuticals Co. Ltd. from 2019 to 2024. For live valuation and market cap data, see market cap of ChengDa Pharmaceuticals Co. Ltd..
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.15 Billion ≈ $313.98 Million |
-5.85% |
| 2023-12-31 | CN¥2.28 Billion ≈ $333.48 Million |
+2.84% |
| 2022-12-31 | CN¥2.22 Billion ≈ $324.28 Million |
+318.19% |
| 2021-12-31 | CN¥529.93 Million ≈ $77.55 Million |
+15.48% |
| 2020-12-31 | CN¥458.91 Million ≈ $67.15 Million |
+28.42% |
| 2019-12-31 | CN¥357.35 Million ≈ $52.29 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to ChengDa Pharmaceuticals Co. Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 169.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥312.18 Million | 14.57% |
| Other Components | CN¥1.83 Billion | 85.43% |
| Total Equity | CN¥2.14 Billion | 100.00% |
ChengDa Pharmaceuticals Co. Ltd. Competitors by Market Cap
The table below lists competitors of ChengDa Pharmaceuticals Co. Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Genus Power Infrastructures Limited
NSE:GENUSPOWER
|
$933.69 Million |
|
Green Plains Renewable Energy Inc
NASDAQ:GPRE
|
$933.75 Million |
|
Middlesex Water Company
NASDAQ:MSEX
|
$933.95 Million |
|
Yuanli Chemical Group Co Ltd
SHG:603217
|
$935.11 Million |
|
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS
IS:GENIL
|
$933.30 Million |
|
Shanxi Guoxin Energy Co Ltd A
SHG:600617
|
$932.75 Million |
|
SEP Analytical (Shanghai) Co. Ltd.
SHE:301228
|
$932.42 Million |
|
Sagicor Financial Company
TO:SFC
|
$932.19 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ChengDa Pharmaceuticals Co. Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,277,123,782 to 2,143,050,905, a change of -134,072,877 (-5.9%).
- Net loss of 28,103,664 reduced equity.
- Dividend payments of 30,548,289 reduced retained earnings.
- Other factors decreased equity by 75,420,924.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-28.10 Million | -1.31% |
| Dividends Paid | CN¥30.55 Million | -1.43% |
| Other Changes | CN¥-75.42 Million | -3.52% |
| Total Change | CN¥- | -5.89% |
Book Value vs Market Value Analysis
This analysis compares ChengDa Pharmaceuticals Co. Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.98x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 8.40x to 2.98x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥4.91 | CN¥41.24 | x |
| 2020-12-31 | CN¥3.95 | CN¥41.24 | x |
| 2021-12-31 | CN¥4.56 | CN¥41.24 | x |
| 2022-12-31 | CN¥14.31 | CN¥41.24 | x |
| 2023-12-31 | CN¥14.72 | CN¥41.24 | x |
| 2024-12-31 | CN¥13.85 | CN¥41.24 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ChengDa Pharmaceuticals Co. Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1.31%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -8.44%
- • Asset Turnover: 0.14x
- • Equity Multiplier: 1.14x
- Recent ROE (-1.31%) is below the historical average (11.36%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 15.23% | 18.45% | 0.54x | 1.53x | CN¥18.61 Million |
| 2020 | 26.45% | 32.48% | 0.70x | 1.17x | CN¥75.37 Million |
| 2021 | 18.98% | 24.16% | 0.61x | 1.29x | CN¥47.51 Million |
| 2022 | 4.81% | 25.88% | 0.18x | 1.05x | CN¥-114.96 Million |
| 2023 | 4.00% | 21.96% | 0.17x | 1.08x | CN¥-136.73 Million |
| 2024 | -1.31% | -8.44% | 0.14x | 1.14x | CN¥-242.41 Million |
Industry Comparison
This section compares ChengDa Pharmaceuticals Co. Ltd.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,347,197,696
- Average return on equity (ROE) among peers: 4.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ChengDa Pharmaceuticals Co. Ltd. (301201) | CN¥2.16 Billion | 15.23% | 0.12x | $933.65 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $2.84 Billion | -41.97% | 9.13x | $1.22 Billion |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $638.89 Million | 0.88% | 0.70x | $438.59 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $1.05 Billion | 10.46% | 0.19x | $5.18 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.07 Billion | 3.83% | 0.46x | $2.81 Billion |
| Wedge Industrial Co Ltd (000534) | $1.29 Billion | 11.69% | 1.47x | $2.95 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $13.85 Billion |
| Hainan Haiyao Co Ltd (000566) | $5.08 Billion | 1.71% | 1.08x | $949.23 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $141.91 Million | 11.01% | 0.32x | $391.07 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $994.58 Million | 2.01% | 2.11x | $1.03 Billion |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $332.48 Million | 26.89% | 0.68x | $3.30 Billion |
About ChengDa Pharmaceuticals Co. Ltd.
ChengDa Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates, chemical ingredients, and food and feed additives in China and internationally. It offers process research and development, process optimization, quality and stability research, customized production and other services for pharmaceutical intermediates and APIs; and food… Read more